The true impact of breast magnetic resonance imaging on the management of in situ disease: more is not better

Michael Lallemand*, Morgan Barron, Jason Bingham, Andrew Mosier, Mark Hardin, Vance Sohn

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background The optimal role of breast magnetic resonance imaging (MRI) in the management of ductal carcinoma in situ (DCIS) remains controversial. We sought to better define the impact of breast MRIs when utilized during the workup of DCIS. Methods Patients with biopsy-proven DCIS without any additional invasive disease were prospectively enrolled in the multidisciplinary breast cancer pathway and comprised the study group. Patients who met any additional criteria for MRI screening were excluded. Results From 2008 to 2014, 93 women met the inclusion criteria. 81 patients underwent MRI as part of their workup. One patient benefited from MRI via identification of occult malignancy not previously identified. 35 MRIs identified no additional information whereas 46 had additional findings. These findings led to 23 procedures and 16 negative biopsies; recommendations for 16 radiographic studies that were normal; and influenced nodal sampling in 7 women with 1 positive metastatic focus. Conclusions The routine use of breast MRI for women diagnosed with DCIS has limited benefit. Often, it leads to multiple procedures and studies that are clinically insignificant and delays surgical treatment.

Original languageEnglish
Pages (from-to)127-131
Number of pages5
JournalAmerican Journal of Surgery
Volume213
Issue number1
DOIs
StatePublished - 1 Jan 2017

Keywords

  • DCIS
  • Ductal carcinoma in situ
  • MRI
  • Screening

Fingerprint

Dive into the research topics of 'The true impact of breast magnetic resonance imaging on the management of in situ disease: more is not better'. Together they form a unique fingerprint.

Cite this